Wei Wu
Senior Director, Venture Investments, JJDC at Johnson & Johnson
San Francisco Bay Area
Overview
Work Experience
Senior Director, Venture Investments, JJDC
2021 - Current
JJDC is the strategic corporate venture capital group for Johnson & Johnson; launched in 1973, it is one of the longest-running and most reputable CVC in health care. I cover investments in areas of strategic interest to Johnson & Johnson. In support of J&J strategic objectives, I work closely with R&D Therapeutic Areas, Innovation Centers, JLabs, Business Development, Commercial, and other functions. 2022-2023, Global assignment in Shanghai China
Johnson & Johnson is a healthcare provider, expertise in innovative medicine and MedTech for every patient & for everyone.
Board Member
2025
Prazer Therapeutics is a biotech company focusing on developing new drugs based on Targeted Protein Degradation (TPD) technology with unique design and characteristics.
Investor
2024
Kaken (TSE: 4521) is a pharmaceutical conglomerate headquartered in Japan with a diverse drug pipeline for various disease areas
Board Member
2023
Circode develops novel RNA therapeutics for multiple disease areas
Board Observer
2022
DAC Biotechnology is an antibody-drug-conjugate (ADC) company that has established an end-to-end capability for ADC generation and an innovative pipeline in pre-clinical and clinical stages.
Board Member
2021 - 2021
ImmPact Bio is pioneering a novel strategy to surmount a major challenge compromising current T-cell (CAR-T) therapy. Acquired by Lyell Immunopharma (LYEL) in 2024.
Board Observer
2020 - 2021
Actym Therapeutics is developing a microbial-based immunotherapy platform for various challenging cancer types.
Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Raised $59,500,000.00 from Boehringer Ingelheim Venture Fund, Panacea Venture, JLo Ventures, Illumina Ventures, GKCC, Korea Investment Partners, Illumina Ventures, JLo Ventures, Boehringer Ingelheim Venture Fund and Panacea Venture.
Senior Associate
2019 - 2021
Illumina Ventures is an independently managed fund focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. We invest in life science tools, therapeutics, clinical diagnostics, and other opportunities to improve human health. Covered investments: Actym Therapeutics, Kallyope, Encoded Therapeutics.
Illumina Ventures visions is to improve human health by unlocking the power of the genome.
Advisory Board Member
2019 - 2020
Immunotherapies for cancer
Director, Healthcare Investment and Business Development
2017 - 2019
BOE Technology Group is a FORBES global2000 company headquartered in Beijing, China. -Lead all aspects of sourcing and deal execution in healthcare business -Manage collaboration projects, investment portfolio, and LP-GP relationship -Recruitment, training, and team building -Corporate strategy and business development -PR/marketing/ecosystem expansion